N-Acetyl-leucyl-leucyl-methioninal

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Acetyl-leucyl-leucyl-methioninal
• 英文别名: A6060；2-acetamido-4-methyl-N-(3-methyl-1-{[4-(methylsulfanyl)-1-oxobutan-2-yl]carbamoyl}butyl)pentanamide；2-acetamido-4-methyl-N-[4-methyl-1-[(4-methylsulfanyl-1-oxobutan-2-yl)amino]-1-oxopentan-2-yl]pentanamide
• 化学式: C₁₉H₃₅N₃O₄S
• 分子量: 401.571
• InChiKey: RJWLAIMXRBDUMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-acetamido-N-[1-[(1-hydroxy-4-methylsulfanylbutan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide 、 吡啶 生成 N-Acetyl-leucyl-leucyl-methioninal
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Kõster Hubert

  公开号：US20100248264A1

  公开（公告）日：2010-09-30

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

  提供了捕获化合物及其集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂的蛋白质混合物。还提供了执行这些方法的自动化系统。
• Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
  申请人：SUNTORY LIMITED

  公开号：EP0504938A2

  公开（公告）日：1992-09-23

  Use of a compound represented by the following general formula (I): wherein R¹ represents a straight or branched acyl group having 2 to 10 carbon atoms, a branched cyclic or bridged cyclic alkyloxycarbonyl group having 4 to 15 carbon atoms, a substituted or unsubstituted benzyloxycarbonyl group, a 2,2,2-trichloroethyloxycarbonyl group, a 2-(trimethylsilyl)-ethyloxycarbonyl group, a p-toluenesulfonyl group, an o-nitrophenylsulfenyl group, a diphenylphosphonothioyl group, a triphenylmethyl group, a 2-benzoyl-1-methylvinyl group or a 4-phenylbutanoyl group; R² represents a hydrogen atom or forms a phthaloyl group together with R¹; R³ represents an isobutyl group, an n-butyl group or an isopropyl group; R⁴ represents an n-butyl group or an isobutyl group; X represents a direct bond, a methionine residue, a leucine residue or a norleucine residue; and H at the C-terminal means that the carboxyl group is reduced in the form of the aldehyde; as an active ingredient for the preparation of a pharmaceutical composition useful in preventing or treating malignant hypercalcemia, bone Paget's disease or osteoporosis.

  使用以下通式 (I) 所代表的化合物： 其中 R¹ 代表具有 2 至 10 个碳原子的直链或支链酰基、具有 4 至 15 个碳原子的支链环状或桥接环状烷氧基羰基、取代或未取代的苄氧基羰基、2,2、2-三氯乙基氧羰基、2-（三甲基硅基）乙基氧羰基、对甲苯磺酰基、邻硝基苯磺酰基、二苯基膦酰基、三苯基甲基、2-苯甲酰基-1-甲基乙烯基或 4-苯基丁酰基； R² 代表氢原子或与 R¹ 共同形成邻苯二甲酰基； R³ 代表异丁基、正丁基或异丙基； R⁴ 代表一个正丁基或一个异丁基； X 代表直接键、蛋氨酸残基、亮氨酸残基或去甲亮氨酸残基；及 C 末端的 H 表示羧基以醛的形式被还原； 作为制备药物组合物的活性成分，可用于预防或治疗恶性高钙血症、骨髓鞘病或骨质疏松症。
• Treatments and diagnostics for cancers
  申请人：Wayne State University

  公开号：US10682362B2

  公开（公告）日：2020-06-16

  Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).

  本文介绍了对实体癌和液态癌有疗效的治疗方法和诊断方法。治疗方法采用加特龙和蛋白酶体抑制剂的联合疗法。诊断方法可以测量雄激素受体（AR）的裂解产物，包括AR-变异体7（AR-V7）裂解产物、聚（ADP-核糖）聚合酶（PARP）裂解产物和/或Spectrin α2裂解产物或血液样本中DUB活性的抑制，以监测对抗阉割性前列腺癌（CRPC）或多发性骨髓瘤（MM）的疗效。
• Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
  申请人：Dyax Corp.

  公开号：US10870115B2

  公开（公告）日：2020-12-22

  Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.

  本文公开了包含液态蛋白酶抑制剂鸡尾酒的抽真空采血管及其用途，用于评估受试者体内与接触系统相关的特征，包括接触系统活化的内源性水平、治疗过程中针对接触系统成分的药物的内源性水平和/或此类药物的免疫原性。
• Novel stimulation of gene expression and protein synthesis of heat shock protein 72/73 (Hsp 70)
  申请人：The Trustees of Columbia University

  公开号：US20020111314A1

  公开（公告）日：2002-08-15

  This invention provides a method for increasing the level of heat shock protein in a cell which comprises contacting the cell with an effective amount of N-acetyl-leucyl-leucyl-norleucinal, so as to thereby increase the level of heat shock protein in the cell. This invention further provides a protein characterized by increased levels of the protein in a cell in response to contacting the cell with an effective amount of N-acetyl-leucyl-leucyl-norleucinal. This invention also provides a method for increasing the binding of apoprotein B100 to a heat shock protein in a cell. This invention provides a method of preserving an organ ex vivo, which comprises contacting the organ with an effective amount of N-acetyl-leucyl-leucyl-norleucinal. This invention also provides a method of preserving an organ in vivo, which comprises contacting the organ with an effective amount of N-acetyl-leucyl-leucyl-norleucinal.

  本发明提供了一种提高细胞中热休克蛋白水平的方法，该方法包括使细胞与有效量的 N-乙酰基-亮氨酰-亮氨酰-正亮氨酰接触，从而提高细胞中热休克蛋白的水平。本发明进一步提供了一种蛋白质，其特征是细胞与有效量的 N-乙酰基-亮氨酰-亮氨酰-正亮氨酰接触后，细胞中该蛋白质的含量增加。本发明还提供了一种增加细胞中载脂蛋白 B100 与热休克蛋白结合的方法。本发明提供了一种体内外保存器官的方法，该方法包括使器官与有效量的 N-乙酰基-亮氨酰-亮氨酰-正亮氨酰接触。本发明还提供了一种体内保存器官的方法，该方法包括使器官与有效量的 N-乙酰基-亮氨酰-亮氨酰-正亮氨酰接触。